Macugen research: Enrollment ends early in trials for wet AMD drug

New York-Eyetech Pharmaceuticals Inc. has completed enrollment in two phase III trials of Macugen, its treatment for wet age-related macular degeneration (AMD), and has received $54.2 million from investors for further development of the drug.